Long-term pegvisomant therapy for acromegaly can lead to a sustained increase in adiposity but no change in skeletal muscle mass, according to a study recently published in Journal of the Endocrine Society. Researchers led by Pamela U. Freda, MD, of the Columbia University Department of Medicine in New York, point out that pegvisomant, a growth...
Heart disease and infections rank as top causes of death among those with rare disorder Endogenous Cushing’s syndrome, a rare hormonal disorder, is associated with a threefold increase in death, primarily due to cardiovascular disease and infection, according to a study presented at ENDO 2021. The research, according to the study authors, is the largest...
Data from a Phase 3 trial presented this week at ENDO2021 showed that octreotide capsules improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly. The data went on to show that 90% of patients receiving octreotide capsules elected to enroll in the open-label extension (OLE)...
Patients with acromegaly provide a unique challenge to endocrine clinicians. Shlomo Melmed, MB, ChB, discusses the latest breakthroughs in treating these patients which includes newly approved pharmaceuticals in his session, “Update on Acromegaly: Treatment Based on the New Guidelines.” This year, the Endocrine Society’s Clinical Endocrinology Update (CEU) will take place online as the COVID-19...
When the Endocrine Society launches ENDO Online 2020 in June, attendees will be treated to Mirjam Christ-Crain, MD, PhD, from the University of Basel, Switzerland, who will discuss the top pituitary research studies in her session, “The Year in Pituitary: Clinical and Research Breakthroughs.” For such a miniscule structure, the pea-sized hypophysis plays an outsized...
For the fifth year in a row, Endocrine News spoke with editors from Endocrine Society journals to get the scoop on the top endocrine discoveries of 2019. Here is part 8 of Eureka! 2019. From April, “DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors,” by Picó, A., et. al. was selected by The...
I wasn’t really very aware of my own … hormones, that is. But by the time I was studying human biology at Oxford Brookes University, I knew that hormones were what I found most interesting, probably because of a combination of having a gun-toting cell physiology professor and a Chilean pharmacologist with a wonderful voice who...
A variety of cases will be presented at ENDO 2019 that will demonstrate how certain endocrine treatments can cause or worsen addictive behaviors. Ashley Grossman, MD, FRCP, discusses how with a little bit of detective work, endocrinologists can understand the underlying circumstances that cause these erratic actions. Ashley Grossman, MD, FRCP, of Oxford University in...
I wasn’t really very aware of my own … hormones, that is. But by the time I was studying human biology at Oxford Brookes University, I knew that hormones were what I found most interesting, probably because of a combination of having a gun-toting cell physiology professor and a Chilean pharmacologist with a wonderful voice who...
